Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 27 Jun 2015 New trial record